Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?
- 13 July 2018
- journal article
- research article
- Published by Bioscientifica in European Thyroid Journal
- Vol. 7 (5) , 243-250
Abstract
Objectives: According to one hypothesis, the popularity of levothyroxine (L-T4)/liothyronine (L-T3) combination therapy relates to weight loss. The purpose of this study was to detect a possible correlation between thyroid-related quality of life (QoL) and weight loss in hypothyroid patients switched from L-T4 monotherapy to L-T4/L-T3 combination therapy. Methods: In an open-label cohort study, all hypothyroid patients referred to the University Hospital endocrine clinic due to persistent symptoms despite adequate L-T4 monotherapy (without other explanations for the symptoms) were switched from L-T4 monotherapy to L-T4/ L-T3 combination therapy at a ratio of approximately 17/1. At baseline and after 3 months of treatment we measured: QoL by the Thyroid Patient-Reported Outcome (ThyPRO-39) questionnaire, thyroid hormones, body weight, body composition by a DEXA-scan, and cognitive function by evaluating participants’ reaction time as well as working memory by the California Computerized Assessment Package (CalCAP®). QoL was re-evaluated after 12 months. Results: Twenty-three patients participated (91% women, median age 47 years). The ThyPRO-39 composite score decreased from a median of 54 (quartiles: 34, 74) to 15 (11, 28) after 3 months (p < 0.0001), and 20 (14, 26) after 12 months, indicating a better QoL. There was no change in body weight, and no correlations between QoL and weight. There was a slight improvement in cognitive function, whereas body composition, heart rate, and serum TSH did not change. Conclusion: Our study on hypothyroid patients switched from L-T4 monotherapy to L-T4/L-T3 combination therapy showed a substantial improvement in QoL measured by the ThyPRO-39. This improvement could not be explained by weight loss.Keywords
This publication has 18 references indexed in Scilit:
- Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and TreatmentFrontiers in Endocrinology, 2017
- Disease-Specific as Well as Generic Quality of Life Is Widely Impacted in Autoimmune Hypothyroidism and Improves during the First Six Months of Levothyroxine TherapyPLOS ONE, 2016
- There is no ‘universal fit’: Reflections on the use of l-triiodothyronine in the treatment of hypothyroidismMetabolism, 2015
- Treating Hypothyroidism with Thyroxine/Triiodothyronine Combination Therapy in Denmark: Following Guidelines or Following Trends?European Thyroid Journal, 2015
- Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case–control studyEuropean Journal of Endocrinology, 2014
- The Thyroid-Related Quality of Life Measure ThyPRO Has Good Responsiveness and Ability to Detect Relevant Treatment EffectsThe Journal of Clinical Endocrinology & Metabolism, 2014
- Falling Threshold for Treatment of Borderline Elevated Thyrotropin Levels—Balancing Benefits and RisksJAMA Internal Medicine, 2014
- Weight Loss after Therapy of Hypothyroidism Is Mainly Caused by Excretion of Excess Body Water Associated with MyxoedemaThe Journal of Clinical Endocrinology & Metabolism, 2011
- Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPROEuropean Journal of Endocrinology, 2010
- THE POWERFUL PLACEBOJAMA, 1955